| Literature DB >> 22456598 |
Johanna Lepeule1, Francine Laden, Douglas Dockery, Joel Schwartz.
Abstract
BACKGROUND: Epidemiologic studies have reported associations between fine particles (aerodynamic diameter ≤ 2.5 µm; PM2.5) and mortality. However, concerns have been raised regarding the sensitivity of the results to model specifications, lower exposures, and averaging time.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22456598 PMCID: PMC3404667 DOI: 10.1289/ehp.1104660
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Number of participants, mortality, and average PM2.5 levels in the Harvard Six Cities study, 1974–2009.
| Characteristic | Six cities (combined) | Steubenville | Kingston–Harriman | St. Louis | Watertown | Topeka | Portage–Wyocena–Pardeeville |
|---|---|---|---|---|---|---|---|
| Participants (n) | 8,096 | 1,346 | 1,258 | 1,292 | 1,332 | 1,238 | 1,630 |
| Person-years (n) | 212,067 | 33,276 | 33,067 | 32,225 | 36,818 | 32,877 | 43,804 |
| Cause of death | |||||||
| All causes [n (%)] | 4,495 (55.5) | 822 (61.1) | 733 (58.3) | 827 (64.0) | 700 (52.6) | 617 (49.8) | 796 (48.8) |
| Cardiovascular (%) | 40.8 | 45.3 | 41.1 | 42.2 | 39.3 | 37.4 | 38.6 |
| Lung cancer (%) | 7.8 | 9.0 | 8.0 | 8.7 | 6.6 | 7.3 | 6.8 |
| COPD (%) | 5.5 | 4.9 | 7.0 | 5.1 | 4.9 | 7.3 | 4.6 |
| 1974–2009 average of individual PM2.5 concentrations | 15.9 | 23.6 | 19.1 | 16.7 | 14.0 | 12.2 | 11.4 |
Figure 1Annual mean PM2.5 levels during 1974–2009 in the Harvard Six Cities study.
Adjusteda association between PM2.5b and mortality, for the 8,096 participants and certain subpopulations of the Harvard Six Cities study, 1974–2009.
| Cause of death/stratum-specific estimates according to characteristics at enrollment | n participants (n person-years) | RR (95% CI) for 10-µg/m3 increase in PM2.5 | |||
|---|---|---|---|---|---|
| All-cause | 8,096 (212,067) | 1.14 (1.07, 1.22) | |||
| Chronic conditionsc | |||||
| Hypertension | 1,439 (30,540) | 1.17 (1.03, 1.32) | |||
| COPD | 942 (17,723) | 1.09 (0.95, 1.26) | |||
| Diabetes | 563 (11,473) | 1.04 (0.85, 1.27) | |||
| Smoking status (p-interaction = 0.58) | |||||
| Never smoker | 3,265 (90,372) | 1.09 (0.98, 1.21) | |||
| Former smoker | 1,934 (48,049) | 1.17 (1.04, 1.30) | |||
| Current smoker | 2,897 (73,646) | 1.17 (1.06, 1.28) | |||
| Follow-up period (p-interaction = 0.06) | |||||
| 1974–1982 | 8,096 (58,798) | 1.06 (0.96, 1.17) | |||
| 1983–1991 | 7,478 (63,129) | 1.32 (1.16, 1.50) | |||
| 1992–2000 | 6,391 (51,800) | 1.11 (0.98, 1.27) | |||
| 2001–2009 | 4,910 (38,340) | 1.19 (0.91, 1.55) | |||
| Cardiovascular | 7,961 (195,941) | 1.26 (1.14, 1.40) | |||
| Smoking status (p-interaction = 0.45) | |||||
| Never smoker | 3,232 (83,861) | 1.21 (1.04, 1.41) | |||
| Former smoker | 1,891 (44,205) | 1.21 (1.02, 1.44) | |||
| Current smoker | 2,838 (67,875) | 1.36 (1.17, 1.58) | |||
| Follow-up period (p-interaction = 0.07) | |||||
| 1974–1982 | 7,961 (42,672) | 1.08 (0.92, 1.27) | |||
| 1983–1991 | 7,478 (63,129) | 1.46 (1.21, 1.76) | |||
| 1992–2000 | 6,391 (51,800) | 1.30 (1.06, 1.59) | |||
| 2001–2009 | 4,910 (38,340) | 1.57 (1.01, 2.43) | |||
| Lung cancer | 7,961 (195,941) | 1.37 (1.07, 1.75) | |||
| Smoking status (p-interaction = 0.15) | |||||
| Never smoker | 3,232 (83,861) | 1.25 (0.54, 2.89) | |||
| Former smoker | 1,891 (44,205) | 1.96 (1.29, 2.99) | |||
| Current smoker | 2,838 (67,875) | 1.25 (0.95, 1.64) | |||
| Follow-up period (p-interaction = 0.19) | |||||
| 1974–1982 | 7,961 (42,672) | 1.45 (0.98, 2.15) | |||
| 1983–1991 | 7,478 (63,129) | 0.94 (0.58, 1.52) | |||
| 1992–2000 | 6,391 (51,800) | 1.54 (0.98, 2.41) | |||
| 2001–2009 | 4,910 (38,340) | 2.84 (1.06, 7.59) | |||
| COPD | 7,805 (180,106) | 1.17 (0.85, 1.62) | |||
| Smoking status (p-interaction = 0.35) | |||||
| Never smoker | 3,191 (77,422) | 0.85 (0.36, 2.02) | |||
| Former smoker | 1,847 (40,453) | 1.64 (0.92, 2.93) | |||
| Current smoker | 2,767 (62,231) | 1.10 (0.74, 1.62) | |||
| Follow-up period (p-interaction = 0.35) | |||||
| 1974–1982 | 7,805 (26,837) | 0.79 (0.36, 1.72) | |||
| 1983–1991 | 7,478 (63,129) | 1.52 (0.90, 2.56) | |||
| 1992–2000 | 6,391 (51,800) | 1.31 (0.74, 2.31) | |||
| 2001–2009 | 4,910 (38,340) | 0.68 (0.25, 1.83) | |||
| aCox proportional hazards model stratified by sex, age, and time in the study and adjusted for BMI, education, and smoking history. bPM2.5 moving average was 1 year before death or censure for all-cause deaths, 1–3 years for cardiovascular and lung-cancer deaths, and 1–5 years for COPD deaths. cEstimates restricted to participants with the specified chronic condition. | |||||
Figure 2Survival probabilities under three hypothetical scenarios: participants of the Harvard Six Cities study are exposed to 10, 15, or 20 µg/m3 PM2.5 during the entire follow-up period of 1974–2009.